Pulse Biosciences to present data on NPS technology for treating nBCC
Category: #health  By Pankaj Singh  Date: 2020-01-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pulse Biosciences to present data on NPS technology for treating nBCC

Pulse Biosciences Inc., a bioelectric medicine company, has reportedly announced that it will be presenting its scientific study assessing the clinical and histologic response of NPS™(Nano-Pulse Stimulation™) technology in treating critical cases of nodular nBCC (Basal Cell Carcinoma).

These outcomes are to be presented at the 22nd annual International Master Course on Aging Skin (IMCAS) World Congress, which apparently is the meeting of international experts in plastic surgery, dermatology, and aging science which will meet in Palais des Congrès, Paris, France.

As per sources, the results show the unique ability of NPS technology to remove tumor cells in nBCCs while sparing surrounding healthy tissue. These outcomes will be backed by clinical photos that display favorable cosmetic outcome possible in a short period with reduced potential for scar development as compared to present surgical excision.

The nBCC subtype reported in this study includes 60% of all basal cell carcinomas. Surgical excision is the present standard care of these nodular lesions which can lead to permanent large scars.

Speaking on the data, Dr. Girish Munavalli of Dermatology, Laser & Vein experts of the Carolinas, Charlotte, NC, said that early findings demonstrated promising potential for NPS technology as a novel treatment option for nBCC.

NPS technology has shown similar therapeutic benefit and the added benefit of superior cosmetic results compared to destructive skin cancer treatment modalities, like curettage and excision.

As per Darrin Uecker, CEO and President of Pulse Biosciences, their company is enthusiastic about the impressive results NPS technology is demonstrating in Basal Cell Carcinomas. They are focused on rapidly advancing its development program across multiple clinical applications.

Uecker added that the company’s presence at the IMCAS conference represented its commitment to international commercialization, which aims to extend Pulse’s long-term growth platform and leverage the Nano-Pulse Stimulation Technology to clear malignant and benign lesions.
 

Source Credit - http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-present-data-nano-pulse-stimulation-technology



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Appili gets FDA approval to expand the clinical trial of favipiravir
Appili gets FDA approval to expand the clinical trial of favipiravir
By Pankaj Singh

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application ...

Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
By Pankaj Singh

The Ministry of Health, Saudi Arabia, has reportedly announced that it will begin the third phase of clinical trials for a COVID-19 vaccine, as part of its cooperation with China’s CanSino Biologics Inc. The tria...

Amazon cleared by UK regulators to buy 16% stake in Deliveroo
Amazon cleared by UK regulators to buy 16% stake in Deliveroo
By Pankaj Singh

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to ...